Translate Bio, Inc. (TBIO)


0.00 (0.00%)
Symbol TBIO
Price $37.36
Beta 0.970
Volume Avg. 2.91M
Market Cap 2.811B
Shares () -
52 Week Range 12.5-37.985
1y Target Est -
DCF Unlevered TBIO DCF ->
DCF Levered TBIO LDCF ->
ROE 10.62% Buy
ROA 4.47% Neutral
Operating Margin -
Debt / Equity 119.29% Buy
P/E -
P/B 6.81 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest TBIO news

Mr. Ronald Renaud
Nasdaq Global Select

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.